No Data
The price of natural bezoar has risen under pressure, and Zhangzhou Pientzehuang Pharmaceutical's profit growth rate has returned to that of ten years ago.
The "Medicine Mace" Zhangzhou Pientzehuang Pharmaceutical (600436.SH) is entering a "slowdown" period. On January 24th, Zhangzhou Pientzehuang Pharmaceutical released the 2024 performance brief...
The rise in raw material costs has led to a slowdown in the net profit growth of Zhangzhou Pientzehuang Pharmaceutical in 2024.
Encountering a Waterloo.
Announcement of Zhangzhou Pianziying Pharmaceutical Co., Ltd. on the 2024 Annual Results Report
Express News | Zhangzhou Pientzehuang Pharmaceutical Prelim 2024 Net Profit up 6.3% Y/Y
Zhangzhou Pientzehuang Pharmaceutical (600436.SH) performance report: Net income for 2024 is 2.974 billion yuan, a year-on-year increase of 6.32%.
On January 23, Gelonghui announced that Zhangzhou Pientzehuang Pharmaceutical (600436.SH) released its annual performance report for 2024. The total operating income during the reporting period was 10.769 billion yuan, a year-on-year increase of 7.06%; the Net income attributable to shareholders of the listed company was 2.974 billion yuan, a year-on-year increase of 6.32%. The main reason for the year-on-year growth of the company's total operating income by 7.06% is due to the strengthening of market planning and expansion of sales channels, and the increase in sales of core products, including the Pientzehuang series and the Pientzehuang brand An Gong Niu Huang Wan. The income of the pharmaceutical distribution industry decreased year-on-year due to the combined impact of changes in health insurance policies and a shrinking consumer market, excluding pharmaceutical distribution.
Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Business Is Yet to Catch Up With Its Share Price
102884128 : getting disappointed with this counter. every day drop.